London, 24 September 2014: TechNavio, the independent tech-focused global research firm, has published a report on the Global Pancreatic Cancer Market 2014-2018, which is expected to post a CAGR of 10.7 percent during the period 2013-2018.
“Combination therapies which target distinct mechanisms are highly efficacious in treating cancer,” says Faisal Ghaus, Vice President of TechNavio.
“Targeting multiple pathways might also reduce the risk of developing treatment-resistant cancers. The increasing use of combination therapies is anticipated to drive the market owing to enhanced safety profile.”
Key Market Drivers
- Unmet Medical Need
- Increase in Awareness
- Novel Mechanisms Targeted by Pipeline Molecules
Key Market Trends
- Use of Combination Therapies
- Use of Targeted Therapies
Key Market Vendors
- Celgene Corp.
- Eli Lilly and Co.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Pfizer Inc.
To define the market circumstances in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3E%C2%A0%3C/p%3E%3Cp%3EIf%20you%20are%20in…
